FIELD: medicine, neurology, in particular treatment of disseminated sclerosis.
SUBSTANCE: complex therapy includes plasma exchange, interferonotherapy, administration of copaxon, cytostatics, symptomatic and bracing agents, and cyclosporin A. Administration of steroids is excluded. Additionally ceruloplasmine intravenously drop-by-drop in dose of 100 mg and cerebrolysate intramuscularly in dose of 10 ml for 10 days are administered. Claimed method provides stable remission up to 12 months for 89.2 % of patients.
EFFECT: decreased invalidisation due to reconstitution of regulatory relationship between nervous and immune systems.
1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| METHOD OF TREATING MULTIPLE SCLEROSIS IN CHILDREN | 2015 |
|
RU2596792C1 |
| TREATMENT OF MULTIPLE SCLEROSIS ACCORDING TO THE METHOD OF KRIVOPALOV-MOSKVIN | 2018 |
|
RU2702120C1 |
| METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
| METHOD FOR PREDICTION OF DEVELOPING MULTIPLE SCLEROSIS TAKING INTO ACCOUNT IMMUNE-METABOLIC VALUES | 2013 |
|
RU2528879C1 |
| ACTH-LIKE PEPTIDE WITH IMMUNOSUPRESSOR FUNCTION | 2017 |
|
RU2681317C1 |
| METHOD OF PATHOLOGICAL PROCESS ACTIVITY DETERMINING IN PATIENTS WITH MULTIPLE SCLEROSIS | 2019 |
|
RU2694614C1 |
| METHOD OF PREDICTING STAGE OF MULTIPLE SCLEROSIS TAKING INTO ACCOUNT INDICATORS OF IMMUNOLOGICAL STATUS | 2023 |
|
RU2811481C1 |
| METHOD FOR PREDICTION OF STAGE OF MULTIPLE SCLEROSIS TAKING INTO ACCOUNT VALUES OF IMMUNOLOGICAL STATUS | 2013 |
|
RU2528882C1 |
| METHOD OF PREDICTING EXACERBATIONS OF REMITTING MULTIPLE SCLEROSIS | 2011 |
|
RU2468370C1 |
